The review found no eligible studies for this question.
The review found no eligible studies for this question.
Maribavir showed no clear difference in CMV disease compared with ganciclovir (low certainty).
Maribavir showed no clear difference in all‐cause death compared with ganciclovir (low certainty).
Maribavir probably leads to higher CMV infection compared with ganciclovir (moderate certainty).
Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).
Maribavir showed no clear difference in acute rejection compared with ganciclovir (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Maribavir showed no clear difference in adverse events compared with ganciclovir (moderate certainty).
Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).
Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).
Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).
Ganciclovir leads to lower CMV disease compared with aciclovir (high certainty).
Rituximab probably leads to lower relapses at 3 months compared with placebo or control (moderate certainty).
Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).